KG BRISTOL, Tenn., Aug. 13 /PRNewswire-FirstCall/ -- King Pharmaceuticals((R)), Inc. (
NYSE: KG) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock ...